Richmond Pharmacology is constantly assessing health and safety risks posed by COVID-19 and is regularly reviewing Public Health England guidance.

Although home-based working is utilized as much as possible, activities such as source data verification can only be performed onsite.

RPL is now welcoming CRA visits to recommence by adhering to the following exposure prevention policy that is designed to best mitigate risks posed by COVID-19.

View Guidelines

Latest news

Richmond Pharmacology Announces Promotion of Dr Priscilla Ochuba to Associate Medical Director

August 1, 2025
Richmond Pharmacology is pleased to announce the promotion of Dr Priscilla Ochuba to Associate Medical Director, effective 1st August 2025.
Read more

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Events

JSCPT 2025

5th –6th December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event